US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Antibe Therapeutics Inc (OP:ATBPF)

N/A UNCHANGED
Last Price Updated: 3:46 PM EDT, Apr 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Antibe Therapeutics Inc

< Previous 1 2 Next >
News headline image
Antibe Therapeutics Announces Amendment to Warrant Terms
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Announces Results of 2021 Annual Meeting
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Provides Clinical Update for Otenaproxesul
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Collaborates With Dalriada Drug Discovery to Accelerate Pipeline Expansion
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership
From Antibe Therapeutics Inc.
Via Business Wire
News headline image
Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
From Antibe Therapeutics Inc.
Via Business Wire
< Previous 1 2 Next >